Inter Pharma Valuation
Is IP-R undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of IP-R when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: IP-R (THB5) is trading above our estimate of fair value (THB0.25)
Significantly Below Fair Value: IP-R is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for IP-R?
Other financial metrics that can be useful for relative valuation.
What is IP-R's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | ฿3.03b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 1.8x |
Enterprise Value/EBITDA | 26.6x |
PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does IP-R's PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 22.1x | ||
KISS Rojukiss International | 19.7x | 14.4% | ฿2.7b |
TNR Thai Nippon Rubber Industry Public | 11.7x | n/a | ฿3.2b |
APCO Asian Phytoceuticals | 46.3x | n/a | ฿4.2b |
S&J S & J International Enterprises | 10.9x | n/a | ฿7.6b |
IP-R Inter Pharma | 110.4x | n/a | ฿3.0b |
Price-To-Earnings vs Peers: IP-R is expensive based on its Price-To-Earnings Ratio (110.4x) compared to the peer average (22.1x).
Price to Earnings Ratio vs Industry
How does IP-R's PE Ratio compare vs other companies in the Asian Personal Products Industry?
Price-To-Earnings vs Industry: IP-R is expensive based on its Price-To-Earnings Ratio (110.4x) compared to the Asian Personal Products industry average (26x).
Price to Earnings Ratio vs Fair Ratio
What is IP-R's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 110.4x |
Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate IP-R's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.